Results 61 to 70 of about 1,753 (162)

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Beyond Histamine: Mast Cell‐Neuron Communication in Chronic Pruritic and Pain Disorders

Experimental Dermatology, Volume 35, Issue 8, August 2026.
ABSTRACT Chronic pruritic and cutaneous pain disorders are increasingly recognized as neuroimmune conditions driven by dynamic interactions between immune and sensory systems. While histamine has historically dominated models of mast cell‐mediated itch, accumulating evidence indicates that non‐histaminergic pathways are central to chronic disease.
Tomer Kagan, Gil Yosipovitch
wiley   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1344-1358, August 2026.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials [PDF]

, 2022
Lebrikizumab, a high-affinity IgG-4 monoclonal antibody targeting interleukin (IL)-13, selectively prevents the formation of the IL-13Ra1/IL-4Ra heterodimer receptor signalling complex.
Silverberg, Jonathan I, Guttman-Yassky, Emma, Blauvelt, Andrew, Simpson, Eric, Liu, Zhuqing T, Gontijo Lima, Renata, Chu, Chia-Yu, Thaçi, Diamant, Seneschal, Julien, Pillai, Sreekumar, Stein Gold, Linda F   +10 more
core   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1359-1371, August 2026.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang, Nicolaas P. A. Zuithoff, Inge M. Haeck, Veroniek E. M. Harbers, Simone Stadhouders‐Keet, Klaziena Politiek, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Hoo‐Yin Lam, Anne‐Moon van Tuyll van Serooskerken, Shiarra M. Stewart, Antoni Gostynski, Annebeth Flinterman, Berit Velstra, Wouter R. H. Touwslager, Francine C. van Erp, Marie L. A. Schuttelaar, Marjolein S. de Bruin‐Weller, Marlies de Graaf   +18 more
wiley   +1 more source

Divergent Paths: A Comprehensive Review of Mechanisms and Clinical Implications in Atopic Dermatitis and Psoriasis

Allergy, Volume 81, Issue 7, Page 2309-2324, July 2026.
ABSTRACT Atopic dermatitis and psoriasis are two common cutaneous chronic inflammatory diseases. Although they share similar immunological mechanisms, their clinical implications in the patient are different. This review compares both diseases from different points of view such as genetics, natural history, triggers of disease, and skin barrier defects
Tali Czarnowicki, Kazunari Sugita, Zenas Yiu, Sandra Díez‐Ribas, Irene Garcia‐Jimenez, Emma Guttman‐Yassky, Luis F. Santamaria‐Babí   +6 more
wiley   +1 more source

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks

Dermatology and Therapy
Background Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients with moderate-to-severe atopic dermatitis (AD).
Gil Yosipovitch, Peter Lio, Franz J. Legat, Raj Chovatiya, Mette Deleuran, Evangeline Pierce, Marta Casillas, Yuxin Ding, Fan E. Yang, Laia Bardolet, Sonja Ständer   +10 more
doaj   +1 more source

Therapy with lebrikizumab for refractory peristomal irritant contact dermatitis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Olivia Danneil, Joachim Dissemond, Finja Reinboldt‐Jockenhöfer   +2 more
wiley   +1 more source

Lebrikizumab may benefit a subset of patients with asthma [PDF]

Thorax, 2011
Interleukin 13 (IL-13), a cytokine of type 2 helper T cells, may contribute to the heterogeneity of asthma in terms of clinical course and response to treatment. IL-13 leads to the production of periostin, a protein that may cause airway remodelling. In this randomised, double-blind, placebo-controlled study, lebrikizumab, a monoclonal antibody that ...
openaire   +1 more source

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Journal of Dermatological Treatment
Aim of the study Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels and stable deep response after ...
Jonathan I. Silverberg, Thomas Bieber, Kilian Eyerich, April W. Armstrong, Brian J. Nickoloff, Chitra R. Natalie, Gaia Gallo, Angela Okragly, Eric Wolf, Chenjia Xu, Brian A. Moser, Maria Jose Rueda, Hany Elmaraghy, Ozge Uluckan, Johann E. Gudjonsson   +14 more
doaj   +1 more source